News
Academy
Publications
All PublicationsE-Books
Media
Editorial PodcastsEditorial VideosPeer ExchangePractice AcademySponsored PodcastsSponsored Videos
More
Conferences
Conference CoverageConference Listing
Columns
All ColumnsA Closing ThoughtClinical Trial InsightsView from BrusselsView from Washington
Resources
AdvertiseBlogsEventsFront & CenterPartner PerspectivesWhite Papers
Webcasts

Subscribe

  • News
  • Academy
  • Publications
  • Media
  • Conferences
  • Columns
  • Resources
  • Webcasts
  • Subscribe
  • Clinical Operations & Strategy
    • Decentralized Clinical Trials
    • Trial Design
    • Investigative Sites
    • CRO/Sponsor
    • Risk-Based Monitoring
    • Protocol Design
    • Clinical Trial Supply Chain
    • Study Start-Up
    • Early Phase Development
  • DEI
    • Industry Initiatives
    • Diversity Action Plans
    • Recruitment
  • Data Management
    • Analytics
    • Electronic Data Capture
    • Real World Evidence
    • Metrics & Benchmarks
  • Patient Participation
    • Integrated Research
    • CRAACO
    • Enrollment
  • Regulatory
    • Institutional Review Board & Ethics Committee
    • FDA
    • EMA
  • Technology
    • Artificial Intelligence/Machine Learning
    • eClinical
    • mHealth
Spotlight -
Conference Coverage|
Peer Exchange|
DE&I|
Editorial Videos|
CNS Drug Development Resources
Advertisement

Currien MacDonald

Advertisement

Medical Chair Director at WCG

Articles by Currien MacDonald

© Egor - © Egor - stock.adobe.com

Engineered Bispecific Antibodies: Regulatory, Ethical, and Best Practice Guidelines

BySharad Adekar, MD, PhD, CIP,Currien MacDonald
October 31st 2025

Ethical and regulatory considerations for safeguarding participants in bispecific antibody clinical trials, and best practices designed to optimize their success.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on Applied Clinical Trials Online

    1

    The Business Case for DEI in Pharmaceutical Innovation: Why Organizational Commitment Matters for Inclusive Clinical Trials

    2

    Why Startup Timelines Are Worsening—and How to Reverse the Trend

    3

    The Evolution of Global Trial Strategies in Today's Complex Healthcare Landscape

    4

    ACT Brief: Signal Durability Redefines RBQM, AI Targets Startup Friction, and CDMOs Advance Patient-Centric Formulation

    5

    Centering Site Experience to Accelerate Study Activation

    • About
    • Advertise
    • Contact Us
    • Editorial Contacts
    • Do Not Sell My Personal Information
    • Privacy Policy
    • Terms and Conditions
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    609-716-7777

    • Applied Clinical Trials
    • BioPharm International
    • Cannabis Science and Technology
    • Chromatography Online
    • Nutritional Outlook
    • Pharmaceutical Commerce
    • Pharmaceutical Executive
    • Pharm Tech
    • Spectroscopy Online
    • Turbo Machinery Magazine
    IS1
    Brand Logo

    © 2025 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us